The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

at Regeneron, explained in the Hansoh deal release. “This is an exciting development in our obesity work at Regeneron, which also includes the muscle-sparing phase 2 COURAGE study investigating ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

The deal, announced Monday ... trial in China and a Phase 2b diabetes study. Regeneron will make an $80 million upfront payment to Hansoh, with potential future payments totaling up to $1.93 ...

Regeneron will pay Hansoh $80m upfront ... Regeneron is expanding its clinical-stage obesity portfolio. The deal is subject to standard closing conditions, including clearances from regulatory ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

The deal, announced Monday ... Ongoing studies include a Phase 3 obesity trial in China and a Phase 2b diabetes study. Regeneron will make an $80 million upfront payment to Hansoh, with potential ...

Is Regeneron stock a buy now? Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will ...